ID: MRFR/Pharma/3161-HCR | February 2021 | Region: Global | 80 pages
Market Synopsis of Global Central Pontine Myelinolysis Market
Central Pontine Myelinolysis (CPM), also known as osmotic demyelination syndrome or central pontine demyelination, is a neurological disorder caused by severe damage of the myelin sheath of neurons. CPM mostly affects the pons area of the brain and is characterized by acute paralysis, difficulty swallowing (dysphagia), difficulty speaking (dysarthria), and other neurological symptoms. These neurological symptoms are manifested into nausea and vomiting, disturbed consciousness, gait changes, confusion, headache, seizures etc. Serious progressive neurological symptoms are the progressive development of spastic tetraparesis, pseudobulbar palsy etc.
The causes of CPM are, rapid correction of low blood sodium levels (hyponatremia) affected by severe liver disease, liver transplant, alcoholism, severe burns, malnutrition, anorexia, severe electrolyte disorders, AIDS, hyperemesis gravidarum, anorexia nervosa, hematopoietic stem cell transplantation, Wernicke encephalopathy etc. The market drivers for central pontine myelinolysis market are increase in the risk factors such as hyponatremia cases, increasing screening and penetration of healthcare, growing income and healthcare expenditure etc. The market restraints are poor cure rates of central pontine myelinolysis, treatment, high cost of treatment etc.
The global CPM market is expected to reach US$ 2.2 billion by 2023, and the market is projected to grow at a CAGR of ~ 5.5 % during the forecast period 2017-2023.
Sources: Mayo Clinic, Healthline Media, U.S. Department of Health and Human Services MRFR Analysis
The global central pontine myelinolysis market has been segmented on the basis of diagnosis, treatment, and end users.
Based on diagnosis, the market has been segmented as magnetic resonance imaging (MRI), computerized tomography (CT), electroencephalography and others.
Based on treatment, the market has been segmented as vitamin supplementation, electrolyte mainainence and others.
Based on the end users, the market has been segmented as hospitals & clinics, academic and research and others.
The Americas account for a significant market share owing to extensive use of medications and high expenditure on the health care driven by the increasing incidence of related diseases and clinical conditions that can cause CPM. Additionally, the fastest uptake of new drugs in the US drives the central pontine myelinolysis market. Also, concentration of major research companies and hospitals in the developed countries of this region is adding fuel to the market growth. The large expenditure on the US healthcare, accounting to 16% of GDP, also cruises the sale of central pontine myelinolysis treatment.
Europe is the second largest market in the world due to high income and healthcare penetration. Europe is led by nations such as Germany and France. UK is expected to be the fastest growing market.
Asia Pacific region is expected to grow rapidly and China and India are likely to lead this market due to fast growing healthcare sector during the forecast period.
Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development.
Key Players in the Global Central Pontine Myelinolysis Market
Some of key players profiled in the report are Fujifilm Holdings Corporation, GE Healthcare, Siemens Healthcare GmbH, Philips Healthcare (Koninklijke Philips N.V.), Shimadzu Corporation, Toshiba Medical Systems Corporation, Carestream Health, Hitachi Medical Corporation and others.
The report for Global Central Pontine Myelinolysis market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.
Frequently Asked Questions (FAQ) :
central pontine myelinolysis market is projected to grow at approximately 5.5% CAGR during the assessment period (2020-2027).
central pontine myelinolysis market is estimated to reach a valuation of approx. USD 2.2 BN by the end of 2023.
increase in the risk factors such as hyponatremia cases and the rising per capita healthcare expenditure, are major tailwinds pushing the growth of the global central pontine myelinolysis market.
North America holds the largest share in the global central pontine myelinolysis market, followed by Europe and the Asia Pacific, respectively.
Fujifilm Holdings Corporation, Philips Healthcare (Koninklijke Philips N.V.), GE Healthcare, Siemens Healthcare GmbH, Toshiba Medical Systems Corporation, Shimadzu Corporation, Carestream Health, and Hitachi Medical Corporation, are some of the top players operating in the global central pontine myelinolysis market.
Table of Contents
1.2 Scope of Study
1.2.1 Research Objective
1.2.2 Assumptions & Limitations
1.3 Market Structure
2. Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
3. Market dynamics
3.4 Macroeconomic Indicators
4. Market factor analysis
4.1 Porters Five Forces Model
4.2 Bargaining Power of Suppliers
4.3 Bargaining Power of Buyers
4.4 Threat of New Entrants
4.5 Threat of Substitutes
4.6 Intensity of Rivalry
5. Global Central Pontine Myelinolysis Market, by Diagnosis
5.2 Magnetic Resonance Imaging (MRI)
5.3 Computerized Tomography (CT)
6. Global Central Pontine Myelinolysis Market, by Treatment
6.2 Vitamin Supplementation
6.3 Electrolyte Mainainence
7. Global Central Pontine Myelinolysis Market, by End Users
7.2 Hospitals & Clinics
7.3 Academic and Research
8. Global Central Pontine Myelinolysis Market, by Region
8.1 North America
8.3 Asia Pacific
8.4 Middle East & Africa
9. Competitive landscape
9.1 Major Strategies Adopted by Market Players
9.1.1 Strategic Partnership
9.1.2 Merger & Acquisition
10. Company profile
10.1 Fujifilm Holdings
10.1.2 Product Overview
10.1.4 Key Developments
10.2 GE Healthcare
10.2.2 Product Overview
10.2.4 Key Developments
10.3 Siemens Healthcare
10.3.2 Product Overview
10.3.4 Key Development
10.4 Janssen Pharmaceuticals
10.4.2 Product Overview
10.4.3 Key Development
10.5 Philips Healthcare
10.5.2 Product Overview
10.5.3 Key Development
10.6 Shimadzu Corporation
10.6.2 Product Overview
10.6.3 Key Development
10.7 Toshiba Medical Systems Corporation
10.7.2 Product Overview
10.7.3 Key Development
10.8 Carestream Health
10.8.2 Product Overview
10.8.3 Key Development
10.9 Hitachi Medical Corporation
10.9.2 Product Overview
10.9.3 Key Development
10.10.2 Product Overview
10.10.3 Key Development
11.1 Key Findings
11.1.1 From CEO’s Viewpoint
11.1.2 Unmet Needs of The Market
11.2 Key Companies to Watch
11.3 Prediction of Central Pontine Myelinolysis Industry